Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature
Abstract
The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.Downloads
Download data is not yet available.
Statistics
- Abstract views: 1403
- PDF: 781
How to Cite
Scrivo, R., Conti, F., Spinelli, F., Truglia, S., Magrini, L., Di Franco, M., Ceccarelli, F., & Valesini, G. (1). Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo, 61(2), 107-117. https://doi.org/10.4081/reumatismo.2009.107
Copyright (c) 1970 R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.